Hologic Announces Financial Results for First Quarter of Fiscal 2025
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2024.
New Report Reveals Alarming Decline in Women’s Cancer Testing Worldwide
Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024.
Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time.
Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2025 on Wednesday, February 5, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Hologic Completes Acquisition of Gynesonics, Inc.
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.
Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC
Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu.
Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines
Hologic, Inc., (Nasdaq: HOLX) a global leader in women’s health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening:
Martin Madaus Elected to Hologic Board of Directors
Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024.
New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence
Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to identify postmenopausal women with hormone-receptor positive (HR+), early-stage, node-negative disease who are at minimal risk of experiencing a distant recurrence. Full results will be shared during Poster Session 1 on December 11, 2024, at 12:30 p.m. CT [#P1-09-13].
Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations
Hologic, Inc. (Nasdaq: HOLX) yesterday presented new research demonstrating the performance of its Genius AI® Detection 2.0 software across diverse patient populations at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).
Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024
Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago on December 1-5. On the show floor and during multiple workshops, Hologic will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection.
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 28, 2024.
Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women’s Health
Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health for approximately $350 million, subject to working capital and other customary closing adjustments.
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, will kick off Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18th year. As part of this annual tradition, Hologic is launching a comprehensive patient education campaign to bust common myths about breast cancer, mammograms and breast density.
Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5th, at 12:20 p.m. Eastern Time.
Hologic Announces Financial Results for Third Quarter of Fiscal 2024
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 29, 2024.
Hologic Completes Acquisition of Endomagnetics Ltd
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million.
72 Million American Women Have Skipped or Delayed Vital Screenings
Millions of women in the United States have missed screenings for serious, often life-threatening conditions, according to a new survey released today by women’s health innovator Hologic, Inc. (Nasdaq: HOLX).
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2024 on Monday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
Hologic Announces Financial Results for Second Quarter of Fiscal 2024
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 30, 2024.
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments.
